Clarithromycin

Clarithromycin

SCHEMBL23854898

CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Clarithromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 9/20 1.00
▸ KCNH2 Q12809 5/20 1.00
▸ ABCB1 P08183 2/20 1.00
▸ SLCO1B3 Q9NPD5 2/20 1.00
▸ SLCO1B1 Q9Y6L6 2/20 1.00
▸ AR P10275 1/20 1.00
▸ MAPK1 P28482 1/20 1.00
▸ MLNR O43193 2/20 0.92
▸ TSHR P16473 2/20 0.92
▸ LMNA P02545 2/20 0.92
▸ TDP1 Q9NUW8 1/20 0.92
▸ ALB P02768 1/20 0.92
▸ CNR1 P21554 1/20 0.92
▸ HTR2A P28223 1/20 0.92
▸ AOX1 Q06278 1/20 0.92
▸ CYP1B1 Q16678 1/20 0.92
▸ ABCC4 O15439 1/20 0.77
▸ ABCB11 O95342 1/20 0.77
▸ PGR P06401 1/20 0.77
▸ HTR1A P08908 1/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clarithromycin SCHEMBL13575758 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL13300525 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL13374687 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL19585126 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL24064961 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL15474392 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL23309064 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL14342512 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL38124 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1
Clarithromycin SCHEMBL14495684 1.00 CYP3A4 (1.00) CYP3A4KCNH2ABCB1SLCO1B3SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11938184-B2 Compositions and methods for treating Crohn's Disease and related conditions and infections Agrawal, Gaurav (AU) 2024-03-26 — — US disclosed
US-20210299254-A1 COMPOSITIONS AND METHODS FOR TREATING CROHN'S DISEASE AND RELATED CONDITIONS AND INFECTIONS CENTRE FOR DIGESTIVE DISEASES (AU) 2021-09-30 — — US disclosed
Send feedback